Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) aimed at expanding the therapeutic pipeline for treating and preventing Alzheimer's disease and related dementias (AD/ADRD) through preclinical validation and drug discovery for novel candidate targets. This initiative will support rigorous research focused on drug target validation and early-stage drug discovery of small molecules, biologics, and emerging therapeutic modalities, utilizing the U01 activity code. The opportunity is significant as it seeks to address critical gaps in the treatment landscape for AD/ADRD, encouraging collaborations among investigators with expertise in these areas. Interested applicants should note that while applications are not currently being solicited, they can prepare for submission as the estimated synopsis post date is July 31, 2026, with a closing date of October 5, 2026, and an anticipated award date of July 1, 2027. For further inquiries, potential applicants can contact the NIH at NIA-NOFO-Scientific@nih.gov.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).